Medication nonadherence.

A $300B+ healthcare problem.1

More than 50% of patients suffering chronic illness do not take their medication as prescribed. This leads to poor patient outcomes, disease progression, and an estimated burden of $100B - $300B1 annually in avoidable direct healthcare costs in the US alone2 , and a $564B burden globally3.

What is adherence?

Adherence is a measure of the extent to which a patient follows a plan agreed upon with their health care provider for the treatment of their health condition. Non-adherence means that patients can struggle to balance their need to take medications against the other demands in their lives.





Our Values: how we will conduct business & deliver against those values

Integrity – we are an ethical company that operates with honesty, trust and respect and conducts our business with the highest of professional standards

Innovation – we are passionate about technology and push the boundaries to continually develop and evolve smart solutions that deliver value to physicians and payers and improve patient’s lives 

Accountability - we are a reliable partner and we hold ourselves accountable for our actions, and deliver on all our commitments

High Performance – we are reliable, collaborative and committed to the highest of standards, keeping quality at the centre of everything we do

Customer Focused – we listen to our customers and continually work to deliver quality products and services, consistently delivering solutions that meet and exceed expectations

The HailieTM Solution (previously known as the Smartinhaler™ Platform) is the world’s most clinically proven asthma and COPD medication adherence solution.

Learn more

Invest in the future of medical.

Adherium is a global leader in digital health technologies, providing patients suffering from chronic disease with solutions to help monitor and achieve optimal adherence. Clinical evidence shows that the use of HailieTM technology (previously known as Smartinhaler™ technology) in asthma substantially increases adherence for preventative and maintenance medications and reduces severe exacerbations in adults and children.

In 2014, global sales revenues in excess of US$36 billion were directly attributable to asthma and COPD. Substantial market opportunities therefore exist for technologies that demonstrate improved adherence and better clinical outcomes, while also potentially optimising the commercial performance of those global pharmaceutical companies that adopt the Hailie™ solution. 

See investor information